1-4 of 4
Paul Hughes
Close
Sort by
Journal Articles

Combined Inhibition of Bcl-2 and Mcl-1 Circumvents Resistance of TP53 Deficient/Mutant AML to BH3 Mimetics

Bing Z Carter, Po Yee Mak, Wenjing Tao, Lauren B Ostermann, Steffen Boettcher, Yuki Nishida, Edward Ayoub, Vivian Ruvolo, Elias J. Jabbour, Paul Hughes, PK Morrow, Michael Andreeff
Journal: Blood
Blood (2021) 138 (Supplement 1): 2239.
https://doi.org/10.1182/blood-2021-148014
Published: 2021
Journal Articles

Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-Resistant and TP53 Mutated AML

Bing Z Carter, PhD, Po Yee Mak, Wenjing Tao, Vivian Ruvolo, MS, Xuan Zhang, PhD, Yuki Nishida, MD PhD, Steven M. Kornblau, MD, Paul Hughes, Xiaoyue Chen, PK Morrow, Michael Andreeff, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 7.
https://doi.org/10.1182/blood-2020-141417
Published: 2020
Journal Articles

Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML

Bing Z Carter, PhD, Po Yee Mak, Vivian Ruvolo, MS, Wenjing Tao, Paul Hughes, Xiaoyue Chen, PK Morrow, Michael Andreeff, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 30–31.
https://doi.org/10.1182/blood-2020-141399
Published: 2020
Journal Articles

Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells

Bing Z Carter, PhD, Wenjing Tao, Po Yee Mak, Qi Zhang, PhD, Xiangmeng Wang, Vinitha Mary Kuruvilla, MSc, Carli Stewart, Vivian Ruvolo, MS, Venkata Lokesh Battula, PhD, Marina Y Konopleva, MD PhD, Sean Caenepeel, Jude Canon, PhD, Paul Hughes, PK Morrow, Michael Andreeff, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1267.
https://doi.org/10.1182/blood-2019-125725
Published: 2019